(“Sintana ”) and Challenger Energy Group plc (“Challenger ”) earlier today, we have reached another milestone associated with our proposed all-share acquisition of Challenger. A Scheme Document in ...

Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial Data reinforces the therapeutic potential and ...

Live webcasts and replays of the Guggenheim and Stifel fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ...

Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended September 30, 2025, ...